grant · indexed from Grants.gov Search API
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
National Institutes of Health
- Published
- 22 Nov 2024
- Deadline
- 19 Nov 2026
- Coverage
- US
National Institutes of Health funding opportunity
Provenance
Indexed from Grants.gov Search API · fetched 29 Jul 2026 · last updated 29 Jul 2026.
Open this grant in the GLODA terminal
The notice above is the public record. Signing in adds the analysis: saved views and alerts on searches like this one, workflow and pipeline, exports and full workspace tooling.